Insights On Enterprise Solutions

  1. Accelerating CAR T-Cell Therapy Manufacturing For Autoimmune Disease 9/7/2026

    Proactive alignment and integrated quality systems can shorten cell therapy timelines. Rapid tech transfer and in-house analytics support regulatory rigor and reduce scaling risks.

  2. When Should You Engage A Cell And Gene Therapy CDMO? Earlier Than You Think 9/7/2026

    Involving manufacturing partners early helps prevent costly bottlenecks. Production expertise strengthens process design, reduces tech transfer risk, and keeps advanced therapy programs on track.

  3. Technology, Not Just Biology, Will Deliver The Future Of Medicine 9/7/2026

    Scaling advanced therapies requires engineering-driven biomanufacturing. Modular automation, standardized platforms, and real-time analytics reduce bottlenecks, speed approvals, and improve access.

  4. Rapid Sterility And Adventitious Agent Testing 9/7/2026

    44-to-72-hour NGS release testing replaces lengthy culture assays, rapidly detecting viral, fungal, and bacterial contaminants to accelerate product release while maintaining patient safety.

  5. Leveraging Protein And gRNA Engineering Of Diverse CRISPR Systems 9/7/2026

    Systematic engineering of CRISPR proteins and guide RNAs boosts adenine base editing efficiency above 85% while minimizing bystander edits, unintended modifications, and off-target activity.

  6. Leveraging Generative AI To Design Novel Deaminases For Base Editing 9/7/2026

    Generative AI and machine learning overcome evolutionary limits to design novel adenine deaminases. These engineered enzymes enable highly specific base editing with minimal bystander activity.

  7. Active Learning-Guided Optimization Of Large Gene Insertion Effectors In Mammalian Cells​ 9/7/2026

    Combining machine and active learning optimizes large serine recombinases in mammalian cells, accelerating effector engineering for targeted gene insertion therapies without structural data.

  8. Next-Generation Enzymes For Targeted Gene Insertion 9/7/2026

    Mining novel recombinases and retrotransposases expands gene-targeting options. AI-driven design improves enzyme activity and specificity, enabling precise, efficient gene insertion.

  9. How To Overcome Early Development Challenges Before They Impact Your Program 9/3/2026

    Poor manufacturability and immunogenicity can delay development. Learn how early developability assessments support IND readiness.

  10. How Sponsors Should Evaluate Manufacturing Resilience 9/3/2026

    Learn how continuity planning, technology transfer capabilities, global network flexibility, and digital visibility contribute to resilient supply chains and help protect programs from disruption.